Imperial College London

DrAbbasDehghan

Faculty of MedicineSchool of Public Health

Reader in Cardiometabolic Disease Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3347a.dehghan CV

 
 
//

Location

 

157Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ricketts:2011,
author = {Ricketts, SL and Rensing, KL and Holly, JM and Chen, L and Young, EH and Luben, R and Ashford, S and Song, K and Yuan, X and Dehghan, A and Wright, BJ and Waterworth, DM and Mooser, V and Waeber, G and Vollenweider, P and Epstein, SE and Burnett, MS and Devaney, JM and Hakonarson, HH and Rader, DJ and Reilly, MP and Danesh, J and Thompson, SG and Dunning, AM and van, Duijn CM and Samani, NJ and McPherson, R and Wareham, NJ and Khaw, KT and Boekholdt, SM and Sandhu, MS},
journal = {International Journal of Molecular Epidemiology and Genetics},
pages = {261--285},
title = {Prospective study of insulin-like growth factor-I, insulinlike growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease},
volume = {2},
year = {2011}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Although experimental studies have suggested that insulin-like growth factor I (IGF-I) and its binding protein IGFBP-3 might have a role in the aetiology of coronary artery disease (CAD), the relevance of circulating IGFs and their binding proteins in the development of CAD in human populations is unclear. We conducted a nested case-control study, with a mean follow-up of six years, within the EPIC-Norfolk cohort to assess the association between circulating levels of IGF-I and IGFBP-3 and risk of CAD in up to 1,013 cases and 2,055 controls matched for age, sex and study enrolment date. After adjustment for cardiovascular risk factors, we found no association between circulating levels of IGF-I or IGFBP-3 and risk of CAD (odds ratio: 0.98 (95% CI 0.90-1.06) per 1 SD increase in circulating IGF-I; odds ratio: 1.02 (95% CI 0.94-1.12) for IGFBP-3). We examined associations between tagging single nucleotide polymorphisms (tSNPs) at the IGF1 and IGFBP3 loci and circulating IGF-I and IGFBP-3 levels in up to 1,133 cases and 2,223 controls and identified three tSNPs (rs1520220, rs3730204, rs2132571) that showed independent association with either circulating IGF-I or IGFBP-3 levels. In an assessment of 31 SNPs spanning the IGF1 or IGFBP3 loci, none were associated with risk of CAD in a meta-analysis that included EPIC-Norfolk and eight additional studies comprising up to 9,319 cases and 19,964 controls. Our results indicate that IGF-I and IGFBP-3 are unlikely to be importantly involved in the aetiology of CAD in human populations.
AU - Ricketts,SL
AU - Rensing,KL
AU - Holly,JM
AU - Chen,L
AU - Young,EH
AU - Luben,R
AU - Ashford,S
AU - Song,K
AU - Yuan,X
AU - Dehghan,A
AU - Wright,BJ
AU - Waterworth,DM
AU - Mooser,V
AU - Waeber,G
AU - Vollenweider,P
AU - Epstein,SE
AU - Burnett,MS
AU - Devaney,JM
AU - Hakonarson,HH
AU - Rader,DJ
AU - Reilly,MP
AU - Danesh,J
AU - Thompson,SG
AU - Dunning,AM
AU - van,Duijn CM
AU - Samani,NJ
AU - McPherson,R
AU - Wareham,NJ
AU - Khaw,KT
AU - Boekholdt,SM
AU - Sandhu,MS
EP - 285
PY - 2011///
SP - 261
TI - Prospective study of insulin-like growth factor-I, insulinlike growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease
T2 - International Journal of Molecular Epidemiology and Genetics
VL - 2
ER -